Hemcheck has received a first evaluation order from Deutsches Herzzentrum Berlin

Hemcheck has received a first evaluation order from Deutsches Herzzentrum Berlin. The order is of lower financial value, but there is an opportunity for additional follow up orders. The order refers to hemolysis detection with regards to diagnostic use.

– We continue the good trend of getting more customers, which is very good news. We see a lot of interest from various hospitals that want to evaluate our products, which also has increased after we CE-marked the products for diagnostic use, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.